Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
Helen Hanson(University of Exeter), Douglas R. Stewart(Cancer Genetics (United States)), William D. Foulkes(McGill University Health Centre), Laura M. Amendola(University of Washington Medical Center), Tuya Pal(Vanderbilt University Medical Center), Susan Klugman(Columbia University), Marc Tischkowitz(University of Cambridge), Nicoleta Voian(Roswell Park Comprehensive Cancer Center), Myra Wick(WinnMed), Joanne Ngeow(Nanyang Technological University), Judith Balmañà(Vall d'Hebron Hospital Universitari), Esteban Astiazarán-Symonds(University of Arizona), Rita K. Schmutzler(University of Cologne), Paul A. James(The Royal Melbourne Hospital)
Cited by 79
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis
|New England Journal of Medicine|2012|1.4k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k